Researchers at the University of Copenhagen – The Faculty of Health and Medical Sciences found that activating a specialized group of neurons within the brainstem of mice restored full movement function in mice with symptoms of Parkinson’s disease.

The CEO of Maryland-based Novavax believes U.S. Emergency Use Authorization (EUA) for the company’s protein-based COVID-19 vaccine could happen “within weeks.”

COVID-19 vaccines using mRNA technology do not affect fertility outcomes during in-vitro fertilization (IVF), researchers found. Other new findings suggest the bacteria living in the small intestine may contribute to the risk for long COVID after infection with SARS-CoV-2.

A study on weight loss suggests that, apart from body mass index (BMI), the likelihood that a person will fail or succeed at shedding the pounds is linked to the genetic makeup of one’s gut microbiome. 

Kaleido Biosciences said on March 24 the company’s experimental oral treatment cut recovery time as well as hospitalizations and emergency room visits in patients with mild to moderate Covid-19, in an early trial.

Kallyope, based in the Alexandria Center for Life Science in New York City, secured $112 million in a Series C financing round that will be used to advance the company’s gut-brain axis field-focused programs into clinical trials.

Leeds, UK-based 4D Pharma and Merck/MSD are developing Live Biotherapeutics vaccines, a new class of medicines.

Less than one month after filing for bankruptcy, uBiome is shutting the Bay Area microbiome company’s doors and selling off assets.

Japan’s Takeda Pharmaceutical presented more data from the company’s Phase IIIb head-to-head VARSITY clinical trial of Entyvio compared to AbbVie’s Humira in ulcerative colitis.

New York-based Kallyope and Danish company Novo Nordisk signed a research collaboration and option deal to discover novel therapeutics to treat obesity and diabetes.